ERBB2 and breast cancer: HR+ HER2− BC is well known for its lack of tumor infiltrating lymphocytes (TILs) and PD-L1 expression and is considered “immune-cold.” Approximately 10–15% of ER+ HER2− BC expresses PD-L1 detected by 22C3 antibody testing [11].